KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other financing activities (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Other financing activities for 5 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 25762.07% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Dec 2025, up 25762.07%, and an annual FY2025 reading of $7.5 million, up 25762.07% over the prior year.
  • Other financing activities was $7.5 million for Q4 2025 at Esperion Therapeutics, up from -$7.5 million in the prior quarter.
  • Across five years, Other financing activities topped out at $7.5 million in Q1 2025 and bottomed at -$7.5 million in Q3 2025.
  • Average Other financing activities over 4 years is $968750.0, with a median of $134500.0 recorded in 2021.
  • The sharpest move saw Other financing activities surged 338.0% in 2022, then soared 25762.07% in 2025.
  • Year by year, Other financing activities stood at $390000.0 in 2021, then tumbled by 212.31% to -$438000.0 in 2022, then surged by 106.62% to $29000.0 in 2024, then skyrocketed by 25762.07% to $7.5 million in 2025.
  • Business Quant data shows Other financing activities for ESPR at $7.5 million in Q4 2025, -$7.5 million in Q3 2025, and $7.5 million in Q1 2025.